Poor
Not Aligned
Patient Risk:
High
Summary
Most statements are generalized about “statins” or compare rosuvastatin vs atorvastatin without being supported by the provided CRESTOR label excerpts. Several label-relevant specifics (e.g., dosing/monitoring, pregnancy/breastfeeding statements, and contraindications) are not accurately mapped to CRESTOR labeling, and no boxed warning content was provided to verify claims about it.
Category Scores
Accurate Statements
Muscle-related symptoms (myalgias) can occur with both statins.
Supported generally by CRESTOR labeling describing myopathy/rhabdomyolysis (Warnings and Precautions 5.1) as an adverse reaction category (6.1). Myalgias are not explicitly quoted in the provided excerpts, but muscle toxicity is supported.
Rare serious muscle injury can occur with both statins.
CRESTOR may cause myopathy and rhabdomyolysis; rare fatalities have occurred (5.1).
Liver enzyme elevations can occur with both statins.
Increases in serum transaminases have been reported with CRESTOR (5.3).
Statins can cause small increases in blood sugar or diabetes risk in some people.
Increases in HbA1c and fasting serum glucose levels have been reported (5.5); JUPITER had higher frequency of diabetes mellitus (6.1).
Unsupported Statements
Rosuvastatin and atorvastatin are statins used to lower LDL cholesterol.
The provided label excerpts are for CRESTOR (rosuvastatin) only; no atorvastatin labeling is supplied.
Rosuvastatin has a reputation for higher LDL-lowering potency than comparable starting doses.
No potency/comparative statement between rosuvastatin and atorvastatin is supported by the provided CRESTOR label excerpts.
Atorvastatin has strong LDL-lowering effects.
Atorvastatin claims are not supported because only CRESTOR labeling excerpts were provided.
Atorvastatin has extensive real-world use.
No such market/real-world utilization information is present in the provided CRESTOR label excerpts.
Both drugs reduce cardiovascular event risk.
CV risk reduction is supported for CRESTOR in the provided label (1 and 14), but the statement claims the same for atorvastatin, which is not supported by supplied labeling.
Both drugs are used for secondary prevention in people who already had heart disease or stroke.
CRESTOR indication is stated as reducing risk of major adverse CV events in adults at increased risk (1), but the label excerpt does not support the specific “heart disease or stroke” phrasing for both drugs or “secondary prevention” wording.
Both drugs are used for higher-risk primary prevention.
Label excerpt supports adults at increased risk for CV events, but does not support “higher-risk primary prevention” wording, and the atorvastatin portion is not supported.
They are not interchangeable dose-for-dose.
No interchangeability/dose equivalence guidance between rosuvastatin and atorvastatin is included in the provided CRESTOR excerpts.
Clinicians commonly base statin selection on potency and target LDL response rather than exact milligram equality.
Practice-pattern statements are not contained in the provided CRESTOR label excerpts.
Rosuvastatin dosing is often started at lower milligram amounts to achieve strong LDL reductions.
The label provides dosing ranges and adjustment guidance, but the claim about “often started” and “strong LDL reductions” is not supported by the provided excerpts.
Atorvastatin can be started at moderate doses and titrated upward as needed.
Atorvastatin dosing/titration is not supported by provided CRESTOR label excerpts.
Periodic monitoring of liver enzymes occurs in some patients receiving statins.
CRESTOR label says consider liver enzyme testing before initiation and when clinically indicated thereafter (5.3), but the claim is generalized and not limited to “before initiation/when clinically indicated,” and does not mention CRESTOR-specific language.
The risk of muscle symptoms can rise with higher doses.
CRESTOR label identifies higher CRESTOR dosage as a risk factor for myopathy (5.1), but the statement is generic about “muscle symptoms” rather than myopathy/rhabdomyolysis; still partially consistent, but not explicitly supported in the provided excerpts for “muscle symptoms” specifically.
The risk of muscle symptoms can rise with drug interactions.
CRESTOR label supports drug interactions as risk factors for myopathy/rhabdomyolysis (5.1) and provides interaction tables (2.6, 7.1), but the exact generic framing about “muscle symptoms” is not explicitly in the excerpts.
Both statins interact with certain medicines.
Drug interaction examples are provided for CRESTOR; the statement includes atorvastatin and is generalized beyond provided CRESTOR-specific labeling.
The specific interaction profile depends on the statin and other medicines taken.
Not explicitly stated in provided CRESTOR excerpts.
If taking certain antibiotics/antifungals, HIV/HCV therapies, or other lipid drugs, interaction risks should be checked before switching between rosuvastatin and atorvastatin.
Switching between specific statins and the listed broad categories are not directly supported by provided CRESTOR excerpts. Provided label excerpts list specific interaction examples (e.g., sofosbuvir combinations, gemfibrozil, cyclosporine).
Switching between atorvastatin and rosuvastatin is typically based on LDL not at goal, side effects (muscle symptoms, lab changes), formulary/cost, adherence issues, or interaction problems.
No such switching criteria/prescribing process is provided in the supplied CRESTOR label excerpts.
A prescriber typically chooses a new starting dose when switching statins.
Not supported by provided CRESTOR label excerpts.
A prescriber typically re-checks lipids after a set interval after switching to confirm reaching the target.
CRESTOR label says assess LDL-C as early as 4 weeks after initiating CRESTOR and adjust dosage (2.1), but “after switching” and “set interval” are not explicitly supported.
Rosuvastatin is more sensitive to kidney function for dosing decisions than atorvastatin.
No comparative kidney sensitivity between rosuvastatin and atorvastatin is supported by supplied CRESTOR excerpts.
If a patient has chronic kidney disease, the prescriber may choose a different starting dose or titration strategy.
CRESTOR label supports dosing adjustments in severe renal impairment (2.5) and identifies renal impairment as a risk factor requiring monitoring (8.6), but the statement is generalized for “chronic kidney disease” without matching the label’s specific “severe renal impairment not on hemodialysis” dosage limits.
If a patient has chronic kidney disease, the prescriber may prefer atorvastatin depending on overall risk and lab results.
Preference for atorvastatin is not supported by CRESTOR labeling excerpts.
Statins are generally avoided during pregnancy.
CRESTOR label states to discontinue when pregnancy is recognized (8.1). The generalized “generally avoided” wording is not directly supported as such.
Statins are generally avoided while breastfeeding.
CRESTOR label recommends breastfeeding is not recommended during treatment (8.2). The generalized “generally avoided” wording is not directly identical to label language.
Cholesterol synthesis is important for fetal development.
While the label states CRESTOR decreases synthesis of cholesterol and may cause fetal harm, the specific rationale phrase is not quoted in the provided excerpts.
Statins have safety concerns during pregnancy and while breastfeeding.
Safety concerns are supported, but the statement is generalized and not tied to CRESTOR-specific mechanisms and instructions.
If pregnancy is possible, a clinician should review risks before starting or continuing either statin.
CRESTOR label excerpt provided includes discontinuation when pregnancy is recognized, but does not provide a “review risks before starting/continuing if pregnancy is possible” instruction in the supplied text.
Both rosuvastatin and atorvastatin have generic versions.
Formulation/market availability and exclusivity are not in the provided CRESTOR label excerpts.
Patent/exclusivity status can affect branded pricing. Generic versions often determine what many patients actually pay.
Pricing/exclusivity information is not in the provided CRESTOR label excerpts.
Statins are used with an emphasis on how aggressively LDL needs to fall (target and current LDL) when choosing between rosuvastatin and atorvastatin.
No comparison or target-selection guidance between rosuvastatin and atorvastatin is provided in CRESTOR excerpts.
Kidney function is a factor clinicians use to choose between rosuvastatin and atorvastatin.
Comparative selection is not supported by provided CRESTOR excerpts.
Interaction risk with other medications is a factor clinicians use to choose between rosuvastatin and atorvastatin.
Comparative selection between specific statins is not supported by provided CRESTOR excerpts.
Prior tolerance (muscle symptoms or lab changes) is a factor clinicians use to choose between rosuvastatin and atorvastatin.
No such comparative prescribing criteria are stated in provided CRESTOR excerpts.
Expected adherence and cost are factors clinicians use to choose between rosuvastatin and atorvastatin.
No adherence/cost prescribing guidance is in provided CRESTOR label excerpts.
Contradictions
Low
AI Statement
If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.
Label Reference
2.1 General Dosage and Administration Information (CRESTOR).
Important Omissions
No statement in the AI response addressed CRESTOR administration specifics (single dose any time of day with or without food; swallow whole; missed dose instruction; antacid timing at least 2 hours before).
Importance:
High
No explicit mention of CRESTOR contraindications (acute liver failure or decompensated cirrhosis; hypersensitivity to rosuvastatin/excipients).
Importance:
High
No explicit CRESTOR-specific monitoring and testing instructions (consider liver enzyme testing before initiation and when clinically indicated; assess LDL-C as early as 4 weeks after initiating; monitor all patients with renal impairment).
Importance:
Moderate
No explicit CRESTOR-specific interaction risk statements and dose limitations for severe interactions (e.g., gemfibrozil dose limits; cyclosporine dose limit) beyond generic claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Generalized and comparison-based claims (rosuvastatin vs atorvastatin) are not supported by CRESTOR label excerpts, and key label-specific contraindications and administration instructions for CRESTOR are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most content is not supported by the provided CRESTOR label excerpts because it discusses atorvastatin and general prescribing patterns rather than CRESTOR-specific labeled instructions, contraindications, and administration/monitoring details.
Suggested Improvement
Restrict claims to CRESTOR labeling excerpts provided: specify CRESTOR indication language, provide labeled contraindications, include labeled administration (missed dose and antacid timing), and replace generic comparison/switching statements with CRESTOR-specific dosing modifications and monitoring/testing instructions from the label.